Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
Oxford Immunotec, part of PerkinElmer, announced that its T-SPOT®.COVID test will be utilized in the COV-AD study, collaborating with the University of Birmingham. This study aims to monitor the SARS-CoV-2 infection and immune responses in patients with antibody deficiencies. Conducted across 13 UK sites, it seeks to determine the outcomes of COVID-19 in immunodeficient patients by assessing their T cell responses and antibody levels. The results could inform vaccination strategies and improve the understanding of immunity in vulnerable populations.
PerkinElmer, a leading global innovator, is hosting a virtual Investor and Analyst Day on June 24, 2021, from 8:30 a.m. to 12:00 p.m. ET. This event will feature key presentations from the senior management team, including updates on current business conditions. Registered attendees can access a live webcast through the Investors section of the company's website. A replay will also be available post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 14,000 people globally.
PerkinElmer (NYSE: PKI) reported strong Q1 2021 results with GAAP earnings per share of $3.37, up from $0.30 in Q1 2020, and revenues of $1.308 billion, a significant increase from $652 million year-over-year. The operating income was $468 million, reflecting a profit margin of 35.8%. Diagnostics revenue soared 236% to $853 million. The company raised its 2021 revenue guidance to $4.37 billion, and EPS forecast to $7.77 for the year.
The Board of Directors of PerkinElmer declared a regular quarterly dividend of $0.07 per share on April 29, 2021. This dividend is set to be paid on August 6, 2021, to shareholders of record as of July 16, 2021.
PerkinElmer reported revenue of approximately $3.8 billion in 2020, boasting a workforce of around 14,000 employees across 190 countries. The company is a component of the S&P 500 Index.
Oxford Immunotec, part of PerkinElmer (NYSE: PKI), announced that its T-SPOT® Discovery SARS-CoV-2 kit will be used in the DIRECT study, which investigates immune responses to COVID-19 in ethnic minority healthcare workers. The study, funded by the National Core Studies group, aims to assess whether vaccination induces a T cell response, potentially revealing disparities in immune responses among different groups. The T-SPOT technology offers advantages over conventional antibody testing, providing critical insights into immunity and potential protection against infection.
Oxford Immunotec, part of PerkinElmer (NYSE: PKI), announced its T-SPOT® Discovery SARS-CoV-2 kit will be utilized in the UK Com-COV trial. This trial, led by the Oxford Vaccine Group, investigates immune responses from different COVID-19 vaccine combinations. Funded by the UK Vaccine Task Force, the trial's first phase has enrolled 830 participants and is expanding to include an additional 1,050. The goal is to evaluate how mixed vaccination schedules enhance immune responses, potentially providing longer-lasting protection against evolving virus variants.
PerkinElmer (NYSE: PKI), a global leader in health innovation, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 9:30 a.m. ET. CEO Prahlad Singh will update on the company's strategic priorities. A live audio webcast will be available on the Investors section of their website, with a replay accessible for 90 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and operates in 190 countries with over 14,000 employees.
PerkinElmer (NYSE: PKI) anticipates a remarkable 98% growth in reported revenue and 90% in organic revenue for Q1 ending April 4, 2021. This performance is attributed to strong core demand, with 10% organic growth in non-COVID-19 segments and approximately $535 million from COVID-19 solutions. Financial results will be disclosed on May 4, 2021, alongside a conference call led by CEO Prahlad Singh and CFO Jamey Mock. Additionally, Steve Willoughby will assume the role of VP of Investor Relations starting May 5, 2021.
PerkinElmer's Horizon Discovery has expanded its gene editing portfolio with new CRISPR modulation (CRISPRmod) reagents, enabling gene repression at the transcriptional level. This includes synthetic single guide RNAs for CRISPR interference and a novel dCas9-SALL1-SDS3 repressor, enhancing gene modulation performance. These advancements aim to aid researchers in understanding disease pathways and exploring therapeutic options. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and serves customers globally.
PerkinElmer, Inc. (NYSE: PKI) has finalized its acquisition of Oxford Immunotec Global PLC, recognized for its T-SPOT®.TB tuberculosis test. The acquisition aims to enhance PerkinElmer's diagnostic capabilities, leveraging automation and commercial access to expand market reach for tuberculosis testing. Oxford Immunotec reported revenues of $73.74 million in 2019. This strategic move aligns with PerkinElmer's mission to innovate for better health outcomes worldwide.
